The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with limited established treatment protocols.
• There is a critical need for effective therapeutic strategies for BPDCN patients.

Observation:

• This study reports on three patients diagnosed with BPDCN who were treated with a combination regimen.
• The regimen consisted of lenalidomide, bortezomib, and dexamethasone administered over five cycles.
• Treatment response was evaluated after the completion of chemotherapy cycles.

Findings:

• Two patients achieved a complete response (CR) to the lenalidomide/bortezomib/dexamethasone therapy.
• One patient achieved a clinical remission (CR) following the treatment.
• These outcomes were observed in a disease context where a consensus treatment is currently lacking.

Implications:

• The observed efficacy suggests that the lenalidomide/bortezomib/dexamethasone regimen may be a valuable therapeutic option for BPDCN.
• These findings warrant further clinical investigation to confirm the regimen's potential in a larger patient cohort.
• The study contributes to the growing body of evidence supporting targeted therapies in rare hematologic malignancies.